06660.HK
AIM Vaccine Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 1.87
+1.63%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−26.0x
Market Cap
HKD 2.28B
MomentumView details →
1D Return
+1.63%
YTD Return
−41.90%
RSI (14)
61.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−26.0x
Market Cap
HKD 2.28B
RSI (14)
61.5
MomentumView details →
1D Return
+1.63%
YTD Return
−41.90%
Similar companies
Latest newsMore news →
Aim Vaccine Co., Ltd. announced its interim results for the six months ended June 30, 2026, with revenue of RMB 351 million, down 31.9% year-on-year, and a narrowed net loss of RMB 123 million compared to a loss of RMB 131 million in the same period last year.12d agoAimi Vaccine submitted a marketing registration application to China's National Medical Products Administration for its self-developed high-titer human diploid cell rabies vaccine, based on positive Phase III clinical trial results.12d agoAimei Vaccine's wholly-owned subsidiary Aimei Honor submitted supplementary materials to the National Medical Products Administration's Center for Drug Evaluation in response to review comments on the market registration application for its serum-free iterative rabies vaccine.33d ago